title: Effect of cilostazol on the neuropathies of streptozotocin-induced diabetic rats.
abstract: OBJECTIVE
  This study examined the effect of cilostazol, a potent phosphodiesterase inhibitor, on the progression of neuropathies associated with streptozotocin-induced diabetes mellitus in Sprague-Dawley rats.
  
  
  METHODS
  Eight weeks after streptozotocin treatment, a pelleted diet containing 0.03% cilostazol (15 mg/kg body weight) was given for four weeks. Body weight, blood glucose level, motor nerve conduction velocity (MNCV), myelinated fiber density and size distribution of sciatic nerves were compared between age-matched normal rats (Group 1), control diabetic rats (Group 2) and cilostazol-treated diabetic rats (Group 3).
  
  
  RESULTS
  Body weight was significantly reduced and blood glucose level was significantly increased in diabetic rats (Group 2 and 3) compared to normal rats. MNCV and cAMP content of sciatic nerves were significantly reduced in diabetic rats 12 weeks after streptozotocin treatment. Myelinated fiber size and density were also significantly reduced, and thickening of the capillary walls and duplication of the basement membranes of the endoneural vessels were observed in the diabetic rats. Whereas both body weight and blood glucose level of Group 3 did not differ significantly from those of Group 2, cilostazol treatment significantly increased MNCV and cAMP content of sciatic nerves in Group 3 but not to the levels observed in Group 1. MNCV positively correlated with cAMP content of sciatic nerves (r = 0.86; p < 0.001). Cilostazol treatment not only restored myelinated fiber density and size distribution but reversed some of the vascular abnormalities.
  
  
  CONCLUSIONS
  These findings suggest that a reduced cAMP content in motor nerves may be involved in the development of diabetic neuropathy, and that cilostazol may prevent the progression of diabetic neuropathy by restoring functional impairment and morphological changes of peripheral nerves.
authors.affiliation: Department of Internal Medicine, Kyung Hee University School of Medicine, Seoul, Korea.
authors.forename: K S
authors.initials: KS
authors.lastname: Suh
authors.forename: S J
authors.initials: SJ
authors.lastname: Oh
authors.forename: J T
authors.initials: JT
authors.lastname: Woo
authors.forename: S W
authors.initials: SW
authors.lastname: Kim
authors.forename: I M
authors.initials: IM
authors.lastname: Yang
authors.forename: J W
authors.initials: JW
authors.lastname: Kim
authors.forename: Y S
authors.initials: YS
authors.lastname: Kim
authors.forename: Y K
authors.initials: YK
authors.lastname: Choi
authors.forename: I K
authors.initials: IK
authors.lastname: Park
mesh_terms: D000818:Animals; D000077407:Cilostazol; D000242:Cyclic AMP / Q000378:metabolism; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy / Q000503:physiopathology; D003929:Diabetic Neuropathies / Q000473:pathology / Q000503:physiopathology / Q000517:prevention & control*; D008297:Male; D009431:Neural Conduction / Q000187:drug effects; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012584:Sciatic Nerve / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D013777:Tetrazoles / Q000494:pharmacology*
chemical_list: D010726:Phosphodiesterase Inhibitors; D013777:Tetrazoles; D000242:Cyclic AMP; D000077407:Cilostazol